Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB). Implantable delivery ensures that drug preparations are directly implanted into the brain by surgery or through special instruments. In cell penetrating peptide mediated BBB crossing, positively charged particles are modified onto the surface of the preparations to heighten the interactions. Temporary disruption of BBB can currently be achieved through ultrasound or magnetic disruption technologies. Intranasal delivery enables drug preparations to cross the olfactory mucosa in the nasal cavity, to be transported into the brain. Finally, molecules, ligands or substrates can be modified onto the surface of the preparations via receptors, carriers or transporter-mediated approaches.
Related content
The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.
This article discusses potential next steps for enhancing clinical trial outcomes in neurodegenerative diseases, with the ultimate goal of improving patient care